Biotechnology

Accelerate drug discovery, enzyme engineering and biological innovation with quantum computing

Biotechnology companies are under constant pressure to develop better therapeutics, engineer more efficient biological processes, and reduce the cost and duration of R&D. Yet as biological systems become increasingly complex, classical computing is reaching its limits.

Quantum computing, combined with AI and advanced computational biology, offers a new way to model molecular interactions with unprecedented accuracy. As fault-tolerant quantum computers become available, organizations that prepare today will be positioned to dramatically accelerate discovery while securing long-term competitive advantage.

Who this applies to

This solution is particularly relevant for organizations in:

• Pharmaceutical research
• Biotechnology
• Synthetic biology
• Industrial biotechnology
• Agricultural biotechnology
• Contract research organizations (CROs)
• Computational biology and bioinformatics teams

The challenge

Developing new therapeutics or engineered biological systems is an expensive and highly uncertain process.

Researchers must predict how proteins, enzymes and small molecules behave in complex biological environments while navigating enormous chemical search spaces. Today’s computational methods rely on approximations that become increasingly inaccurate as molecular complexity grows.

The result is familiar across the industry:

• Long drug discovery timelines
• High late-stage clinical attrition
• Expensive laboratory validation cycles
• Slow enzyme and protein engineering
• Increasing computational costs with diminishing returns

As biological datasets continue to grow, improving AI models alone is no longer sufficient. More accurate molecular simulation is becoming a strategic necessity.

Business impact

Quantum-enhanced biotechnology has the potential to deliver measurable value across the innovation pipeline.

Organizations can expect benefits such as:

• Accelerated drug discovery and lead optimization
• Reduced late-stage development failures
• Lower R&D costs
• Faster engineering of enzymes and biocatalysts
• Improved prediction of protein-ligand interactions
• Shorter time-to-market for therapeutics and bio-products
• More sustainable industrial biotechnology processes

Evaluate your biotech pipeline for quantum advantage

Identify where quantum computing can improve simulation accuracy, accelerate discovery, and complement your existing AI and HPC workflows.

→ Speak with our Quantum Engineering Team

Why classical computing reaches its limits

Many biological simulations require solving quantum mechanical interactions between electrons.

Although techniques such as Density Functional Theory (DFT), molecular dynamics and Free Energy Perturbation (FEP) have transformed computational biology, they rely on approximations that become increasingly expensive—or insufficiently accurate—as systems grow larger.

Several challenges make biological simulation particularly difficult:

Biological complexity
Proteins, enzymes, metabolites and cellular pathways interact across multiple spatial and temporal scales.

Molecular precision
Drug discovery increasingly requires electronic-structure accuracy to correctly predict binding affinities and reaction mechanisms.

Chemical feasibility
Designing promising molecules computationally is only valuable if they can ultimately be synthesized and manufactured.

Complex molecular geometries
Properties such as chirality and conformational flexibility dramatically increase computational complexity.

Dynamic biological environments
Physiological environments introduce highly reactive and constantly changing conditions that are difficult for classical simulations to capture accurately.

The quantum approach

Rather than replacing existing computational workflows, quantum computing extends them.

Hybrid quantum-classical pipelines combine AI, HPC and quantum processors to solve the computationally intensive parts of biological simulation.

Near-term systems already enable organizations to develop expertise and validate workflows. As fault-tolerant quantum computing matures, advanced algorithms such as Quantum Phase Estimation (QPE) will enable significantly more accurate simulations of molecular systems that remain beyond the reach of classical computation.

Organizations that begin building these capabilities today will be better positioned to capitalize as quantum hardware scales.

Representative use cases

Drug discovery and molecular design
Improve the prediction of protein-ligand interactions by combining quantum simulation with AI-driven molecular design.

Potential outcomes include:

• Better candidate selection
• Reduced false positives
• Lower late-stage failure rates
• Faster optimization of lead compounds

Protein and enzyme engineering
Design enzymes with improved catalytic performance for pharmaceutical, agricultural and industrial applications.

Quantum-enhanced molecular simulation can accelerate the discovery of proteins with targeted properties while reducing experimental screening requirements.

Sustainable industrial biotechnology
Develop biological alternatives to energy-intensive industrial chemistry.

Potential applications include:

• High-efficiency biocatalysts
• Plastic-degrading enzymes
• Carbon-efficient manufacturing pathways
• Sustainable chemical production

Synthetic biology
Optimize complex biological pathways used in engineered microorganisms for pharmaceutical manufacturing, specialty chemicals and next-generation biomaterials.

Assess your quantum readiness

Our quantum application engineers can evaluate your computational challenges and identify where hybrid quantum workflows can create measurable business value.

→ Book a technical assessment

Technical deep dive

Quantum computing is particularly well suited to problems involving electronic structure calculations that become computationally prohibitive for classical architectures.

Current hybrid quantum-classical methods leverage variational quantum algorithms alongside AI and high-performance computing to improve molecular simulation workflows.

As fault-tolerant quantum computers become available, algorithms including Quantum Phase Estimation (QPE) are expected to substantially improve the simulation of protein-ligand interactions, enzyme active sites and complex reaction mechanisms by reducing the approximations required by classical methods.

For industrial biotechnology, hybrid quantum machine learning approaches combining variational quantum circuits with classical generative models are also being investigated to accelerate de novo molecular and peptide design for applications such as novel biocatalysts and environmental remediation.